David Guyer, MD - Partner
Focus: Biotechnology
Summary:
David Guyer joined SVLS in 2006. He serves on the Boards of portfolio
companies LenSx Lasers, Lux biosciences, Neovista, Neurotech
and Ophthotech as well as the public company Optos.
Prior Experience:
David co-founded and served as CEO and director for six years
of Eyetech Pharmaceuticals (former Ticker 'EYET') , Inc. a biopharmaceutical
company that specialized in the development and commercialization
of novel therapeutics to treat diseases of the eye. He led the
firm through private financing rounds totaling approximately
$170 million, a $157 million initial public offering and a secondary
financing. The company also developed and gained FDA approval
for Macugen, a product to treat macular degeneration, which Eyetech
partnered with Pfizer in a deal valued at over $750 million.
OSI Pharmaceuticals subsequently acquired Eyetech in a deal valued
at $935 million. Prior to founding Eyetech, Dr. Guyer was professor
and chairman of the department of ophthalmology at the NYU School
of Medicine.
Qualifications:
David received a BSc from Yale College and an MD from Johns
Hopkins Medical School.
